BiomX (PHGE) Profit After Tax (2018 - 2026)
BiomX (PHGE) posted Profit After Tax of -$19.1 million for Q1 2026, up 55.51% sequentially from -$43.0 million in Q4 2025, and down 149.9% YoY from $38.4 million in Q1 2025.
BiomX (PHGE) Profit After Tax (2018 - 2026) Analysis & Trends
BiomX has reported Profit After Tax for 9 years, with the latest figure at -$19.1 million in Q1 2026.
- Quarterly Profit After Tax fell 149.9% year-over-year to -$19.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$77.4 million (down 859.96% YoY) and the FY2025 annual result came in at -$36.2 million, down 104.2% from the prior year.
- Profit After Tax climbed to -$19.1 million in Q1 2026 per PHGE's latest filing, from -$43.0 million in the prior quarter.
- Over five years, Profit After Tax peaked at $9.6 million in Q3 2024 and troughed at -$43.0 million in Q4 2025.
- A 5-year average of -$7.8 million and a median of -$6.6 million in 2022 frame the typical range for Profit After Tax.
- The sharpest annual moves came in 2023 and 2025: Profit After Tax surged 216.61% in 2023, then slumped 235.03% in 2025.
- Over 5 years, Profit After Tax stood at -$5.9 million in 2022, then advanced by 6.71% to -$5.5 million in 2023, then plunged by 164.31% to -$14.5 million in 2024, then plunged by 196.42% to -$43.0 million in 2025, then jumped by 55.51% to -$19.1 million in 2026.
- According to Business Quant data, Profit After Tax over the past three periods registered -$19.1 million, -$43.0 million, and -$9.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -16.62 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | BiomX | 351,774.34 | -816,225.66 | - | -19.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -19.14 Mn |
| Dec 31, 2025 | -43.02 Mn |
| Sep 30, 2025 | -9.17 Mn |
| Jun 30, 2025 | -6.04 Mn |
| Mar 31, 2025 | -7.66 Mn |
| Dec 31, 2024 | -14.51 Mn |
| Sep 30, 2024 | 9.64 Mn |
| Jun 30, 2024 | 4.47 Mn |
| Dec 31, 2023 | -5.49 Mn |
| Sep 30, 2023 | 7.91 Mn |
| Jun 30, 2023 | -6.41 Mn |
| Mar 31, 2023 | -6.36 Mn |
| Dec 31, 2022 | -5.89 Mn |
| Sep 30, 2022 | -6.78 Mn |
| Jun 30, 2022 | -7.48 Mn |
| Mar 31, 2022 | -8.17 Mn |
| Dec 31, 2021 | -10.46 Mn |
| Sep 30, 2021 | -10.03 Mn |
| Jun 30, 2021 | -7.34 Mn |
| Mar 31, 2021 | -8.40 Mn |